1. Updates in the Management of Acute Promyelocytic Leukemia

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Initial Management of Suspected APL

4. Genetics

5. APL Morphology

6. Risk Stratification

7. Effects of Obesity on APL Risk and Prognosis

8. Initial Treatment of Low-Risk APL

9. ATRA/ATO vs AIDA in ND, Low-Risk APL GIMEMA APL0406, Randomized Phase 3 Noninferiority Trial

10. Nonhematologic Toxicity

11. Initial Treatment of High-Risk APL

12. ATRA/ATO/Idarubicin vs AIDA in ND, High-Risk APL APOLLO, Randomized Phase 3 Clinical Trial

13. ATRA/ATO vs AIDA in ND APL AML17, Randomized Phase 3 Clinical Trial

14. Updated Safety Results Select AEs in GIMEMA APL0406 Final Analysis

15. Maintenance in Low-Risk APL

16. Acute Supportive Care Measures for APL

17. Response Evaluation

18. Long-Term Outcomes With ATRA/ATO Treatment

19. Future Directions Chemotherapy-Free, Outpatient Treatment for Low-Risk APL?

20. Key Takeaways

21. Abbreviations

22. Abbreviations (cont)

23. Abbreviations (cont)